Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virological response to adefovir monotherapy and the risk of adefovir resistance.

World journal of gastroenterology - 14 Aug 2011

Sinn Dong Hyun, Lee Hyang Ie, Gwak Geum-Youn, Choi Moon Seok, Koh Kwang Cheol, Paik Seung Woon, Yoo Byung Chul, Lee Joon Hyeok

Abstract excerpt

AIM: To evaluate virological response to adefovir (ADV) monotherapy and emergence of ADV-resistant mutations in lamivudine (LAM)-resistant chronic hepatitis B patients. METHODS: Seventy-seven patients with documented LAM resistance who were treated with 10 mg/d ADV for > 96 wk were analyzed for ADV resistance. RESULTS: At week 48 and 96, eight (10%) and 14 (18%) of 77 LAM-resistant patients developed the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Drug Resistance, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Share to Organophosphonates

Source

Open in PubMed Open full text

Identifiers

PMID: 21941420
DOI: 10.3748/wjg.v17.i30.3526
PMCID: PMC3163251

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virological response to adefovir monotherapy and the risk of adefovir resistance.PMID 21941420Read ↗

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.Semantic proximity Read ↗

Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.Semantic proximity Read ↗

Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.Semantic proximity Read ↗

Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.Semantic proximity Read ↗

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.Semantic proximity Read ↗

Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience.Semantic proximity Read ↗

Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Virologic response and resistance to adefovir in patients with chronic hepatitis B.Semantic proximity Read ↗

Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.Semantic proximity Read ↗

Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.Semantic proximity Read ↗

[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.